Questions and answers on serious non-fatal adverse events and reporting rules
|
|
- Valerie Barton
- 6 years ago
- Views:
Transcription
1 12 April 2017 EMA/CVMP/PhVWP/303762/2012-Rev.1 Committee for Medicinal Products for Veterinary Use Questions and answers on serious non-fatal adverse events and reporting rules This questions and answers document was developed to enable all stakeholders understand what constitutes a serious non-fatal adverse event following use of a veterinary medicinal product (VMP), after recommended or non-recommended use. The document provides guidance on which clinical signs or events should be considered as life-threatening or should be considered as resulting in persistent or significant disability or incapacity or congenital anomaly or birth defect. Some clinical signs may vary according to species. This questions and answers document also provides information on serious adverse event reporting, and complements the guidance included in Volume 9B of The Rules Governing Medicinal Products in the European Union Guidelines on Pharmacovigilance for Medicinal Products for Veterinary Use. 1. What is life-threatening in the context of a serious adverse event? A life threatening adverse event is one in which the animal was at risk of death at the time of the event. 2. What is persistent or significant disability in this context? Disability in this context occurs when an animal or group of animals is unable to accomplish elementary every-day activities. Significant disability also occurs in cases when a veterinarian considers it necessary to administer VMPs that would not normally be used as a treatment of first choice e.g. corticosteroids in order to stop escalation or worsening of clinical signs. Even if treatment is successful and clinical signs of the adverse event are not exacerbated or do not last long, this will also be considered as significant disability. 3. How should (fatal and non-fatal) serious adverse events be reported? Serious fatal or non-fatal adverse events should be reported in an expedited manner, regardless of the causality assessment. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 4. What are the examples of serious non-fatal adverse events? a. There are clinical signs that should automatically lead to classification as serious adverse events as soon as they are reported, regardless of the causality assessment, the outcome, the time to onset etc. (= if it is mentioned, then the adverse event is serious). Some examples are provided below, however please note that this list is not exhaustive: shock (all shock reactions, whatever the origin is: circulatory, anaphylactic etc.). Clinical signs of anaphylaxis may vary according to species. For anaphylactic shock, see Table 1; respiratory distress, dyspnoea, apnoea; collapse, syncope; convulsions/seizures (even if first occurrence); blindness/impaired vision (also temporary); deafness/impaired hearing (also temporary); paralysis, paresis; failure of vital organs (total loss of function); uterine haemorrhage, uterine rupture, or pyometra; ovariohysterectomy or caesarean section/dystocia following lack of expected efficacy (LEE) (e.g. after administration of abortifacient agent); peritonitis; diabetes mellitus; severe fish body deformities; malignant neoplasia (including sarcomas at administration sites); stillbirth, abortion, congenital anomaly or birth defect (excluding dew claws); LEE during euthanasia or anaesthesia; recumbency in large animals. b. Clinical signs or reactions that could be considered serious or non-serious depending on other criteria such as: systemic sequelae; duration; depth, extent, localisation of lesions; physiological context (age of the animal, gestation etc.). Any other information that could make the assessor think that what is reported in the adverse event is a life-threatening situation, or a persistent or significant disability/incapacity. EMA/CVMP/PhVWP/303762/2012-Rev.1 Page 2/5
3 Here are some examples: facial oedema/angioedema or Quincke s oedema: consider if dyspnoea is associated or if serious oedema has also been detected (pulmonary, laryngeal etc.); metabolic and/or endocrinological disorders (elevated renal parameters or liver enzymes etc.): clinical importance has to be considered; haematological disorders: clinical importance has to be considered; cardiac arrhythmia: consider clinical importance (collapse, fatigue etc.); gastro-enteritis; recumbency: consider duration, species; anorexia: consider duration, species (e.g. guinea pigs, rabbits) and consider systemic sequelae; reduced mobility (lameness, decubitus): systemic signs, duration, species to be considered (see also recumbency in large animals in 4a above); injection and application site reactions: systemic signs, localisation, depth and extent of lesions and/or reduced mobility to be considered; acute mastitis with systemic signs or recumbency; metritis; dermatological signs of hypersensitivity reaction (toxic epidermal necrolysis (TEN), Steven-Johnson-syndrome, lupoid onychodystrophy); photosensitisation: systemic signs, localisation, depth and extent of lesions to be considered; pemphigus foliaceous: systemic signs, localisation, depth and extent of lesions to be considered; pancreatitis: systemic signs to be considered; significant reduction in physiological function occurring and lasting for a longer period e.g. reduced milk yield, reduced egg production, reduced growth rate; lack of expected efficacy (LEE): if the LEE results in a life-threatening condition (e.g. cluster seizures in epileptic dogs) or in persistent or significant disability/incapacity of the animal or the group of animals. EMA/CVMP/PhVWP/303762/2012-Rev.1 Page 3/5
4 Table 1 Clinical signs of anaphylactic shock reactions in different species Anaphylactic shock is an acute allergic, potentially life-threatening, Type 1 hypersensitivity reaction resulting from the generalised release of potent vasoactive substances from mast cells and basophils. The clinical signs of anaphylaxis can vary depending on the major so-called shock organ relevant to the species. The table below summarises the differences between species, however this list is not exhaustive. Species Major shock organ(s) Pathology Clinical signs Dogs Liver Hepatic and intestinal engorgement, visceral Initially excitement, urticaria, angioedema and pruritus, then vomiting and defecation. Finally collapse, dyspnoea and convulsions. Cats Respiratory Bronchoconstriction, pulmonary haemorrhage, oedema oedema of the glottis. Initially angioedema and pruritus around the face, then salivation, dyspnoea, vomiting, incoordination and collapse. Horses Respiratory / Pulmonary oedema intestinal oedema and Initially shivering, sweating and incoordination. Possibly coughing, dyspnoea and diarrhoea. Finally collapse. Colic. Cattle and sheep Respiratory / Pulmonary haemorrhage, oedema and emphysema. Initially urticaria, angioedema, pruritus and restlessness. Coughing, severe dyspnoea and cyanosis. Also defecation, urination, bloat and collapse. Pigs Respiratory / Pulmonary oedema intestinal oedema and Dyspnoea, cyanosis, pruritus and collapse. 5. References 1. European Commission (2011) Volume 9B - Pharmacovigilance for Medicinal Products for Veterinary Use Guidelines on Pharmacovigilance for Medicinal Products for Veterinary Use 2. European Parliament and the Council. Directive 2001/82/EC of 6 November 2001 on the Community Code Relating to Medicinal Products for Veterinary Use, as amended by Directives 2004/28 EC, 2009/9/EC and 2009/53/EC in European Commission: The Rules Governing Medicinal Products in the European Union Volume 5 EU pharmaceutical legislation for medicinal products for veterinary use ( EMA/CVMP/PhVWP/303762/2012-Rev.1 Page 4/5
5 3. European Parliament and Council (2004) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. EMA/CVMP/PhVWP/303762/2012-Rev.1 Page 5/5
Metacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.
EMA/CVMP/259397/2006 EMEA/V/C/000033 An overview of Metacam and why it is authorised in the EU What is Metacam and what is it used for? Metacam is an anti-inflammatory medicine used in cattle, pigs, horses,
More informationRecommendation for the basic surveillance of Eudravigilance Veterinary data
1 2 3 25 May 2010 EMA/CVMP/PhVWP/471721/2006 Veterinary Medicines and Product Data Management 4 5 6 Recommendation for the basic surveillance of Eudravigilance Veterinary data Draft 7 Draft agreed by Pharmacovigilance
More informationGuidance notes on the use of VeDDRA terminology for reporting suspected adverse reactions in animals and humans
21 June 2018 EMA/CVMP/PhVWP/288284/2007-Rev.11 Committee for Medicinal Products for Veterinary Use Guidance notes on the use of VeDDRA terminology for reporting suspected adverse reactions in animals and
More informationReflection paper on promotion of pharmacovigilance reporting
13 July 2017 EMA/CVMP/PhVWP/390033/2014-Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on promotion of pharmacovigilance reporting Draft agreed by CVMP Pharmacovigilance
More informationPublic bulletin - Veterinary pharmacovigilance 2010
10 February 2011 EMA/CVMP/PhVWP/44873/2011 Committee for Medicinal Products for Veterinary Use (CVMP) 1. Introduction This is the 8 th bulletin from the European Medicines Agency on veterinary pharmacovigilance
More informationMonthly report on application procedures, guidelines and related documents for veterinary medicines
2 June 7 EMA/3737/7 Veterinary Medicines Division Monthly report on application procedures, guidelines and related documents for May 7 This report, which is updated every month, provides current information
More informationOpinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004
11 December 2014 EMA/CVMP/761582/2014 Veterinary Medicines Division EMEA/V/A/107 Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004
More informationStandard operating procedure
Standard operating procedure Title: Annual review of VeDDRA list to be used in EudraVigilance Veterinary Status: PUBLIC Document no.: SOP/V/4019 Lead author Approver Effective date: 15-MAY-15 Name: Raquel
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationCollie (Rough) Pedigree Breed Health Survey
Collie (Rough) Pedigree Breed Health Survey Forms were received representing 212 living dogs & 37 deceased dogs. Mortality results A total of 37 deaths were reported, representing 0.66% of all deaths reported
More informationANNUAL STATISTICAL REPORT FOR ANIMALS USED IN IRELAND UNDER SCIENTIFIC ANIMAL PROTECTION LEGISLATION
ANNUAL STATISTICAL REPORT FOR ANIMALS USED IN IRELAND UNDER SCIENTIFIC ANIMAL PROTECTION LEGISLATION 2013 CONTENTS 1. Introduction 2. Summary 3. Results 3.1 Species and numbers of naive animals used in
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection
More informationEuropean Medicines Agency role and experience on antimicrobial resistance
European Medicines Agency role and experience on antimicrobial resistance Regional Training Workshop on Antimicrobial Resistance (AMR) Responding to the global challenge of AMR threats: toward a one health
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018
7 December 2017 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018 Chairpersons Chair: D. Murphy Status Adopted in December
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More informationPDP can be completed in the context of small animal, equine or farm animal practice, or any combination of these three.
Clinical procedures checklists DRAFT REVISIONS PDP can be completed in the context of small animal, equine or farm animal practice, or any combination of these three. RCVS YEAR ONE CLINICAL PROCEDURES
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationDraft ESVAC Vision and Strategy
1 2 3 7 April 2016 EMA/326299/2015 Veterinary Medicines Division 4 5 6 Draft Agreed by the ESVAC network 29 March 2016 Adopted by ESVAC 31 March 2016 Start of public consultation 7 April 2016 End of consultation
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationANNUAL STATISTICAL REPORT FOR ANIMALS USED IN IRELAND UNDER SCIENTIFIC ANIMAL PROTECTION LEGISLATION
ANNUAL STATISTICAL REPORT FOR ANIMALS USED IN IRELAND UNDER SCIENTIFIC ANIMAL PROTECTION LEGISLATION 2015 CONTENTS 1. Introduction 2. Summary 3. Results 3.1 Species and numbers of naïve animals used in
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections London, 24 February 2009 EMEA/CVMP/PhVWP/253196/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE EMEA PUBLIC BULLETIN 2008 ON VETERINARY
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Efestad 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. Excipient: 31.5
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Meeting of July 2016
15 July EMA/CVMP/454098/ Press Office Press release Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 12-14 July The Committee elected Helen Jukes from the United Kingdom as its vice-chair
More informationReport from the Kennel Club/ British Small Animal Veterinary Association Scientific Committee
Report from the Kennel Club/ British Small Animal Veterinary Association Scientific Committee Summary results of the Purebred Dog Health Survey for the Finnish Spitz breed Warning: The results of this
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fluclon 250 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250mg of flucloxacillin as flucloxacillin sodium.
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Meeting of December 2016
09 EMA/794393/2016 Press Office Press release Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 06-08 CVMP opinions on veterinary medicinal products The Committee adopted by consensus
More informationESVAC (European Surveillance of Veterinary Antimicrobial Consumption)
ESVAC (European Surveillance of Veterinary Antimicrobial Consumption) Present and future activities 60th Meeting of the EFSA advisory forum Presented J. Torren, Scientific Administrator, Animal and Public
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystatin Orifarm, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients with known effect: - Methyl parahydroxybenzoate
More informationVeterinary pharmacovigilance 2014
2 March 2015 EMA/CVMP/793263/2014 Committee for Medicinal Products for Veterinary Use (CVMP) Public bulletin 1. Executive Summary This public bulletin is aimed at informing veterinarians and the public
More informationPRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 12 to 14 October 2004
European Medicines Agency Veterinary Medicines and Inspections London, 15 October 2004 EMEA/CVMP/973/04 PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 12 to 14 October 2004
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationGuideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market
8 December 2016 EMA/CVMP/QWP/128710/2004-Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on quality data requirements for veterinary medicinal products intended for minor use
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationVICH GL30 on pharmacovigilance of veterinary medicinal products: controlled list of terms
12 December 2013 EMA/CVMP/VICH/647/2001 Committee for Medicinal Products for Veterinary Use (CVMP) VICH GL30 on pharmacovigilance of veterinary medicinal products: controlled list of terms Adoption by
More informationComponents of Modified Kramer System
Components of Modified Kramer System 1. Previous Experience (-1, 0,+1) 2. Alternative Etiologic Candidate (-1, 0, +2) 3. Timing (-2, 0, +1) 4. Overdose (0, +1) 5. Dechallenge (-1, 0, +1) 6. Rechallenge
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Desloratadine Actavis 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine.
More informationVI.B.2 Elements for a public summary. VI.B.2.1 Overview of disease epidemiology
VI.B.2 Elements for a public summary VI.B.2.1 Overview of disease epidemiology [Moxifloxacin] 400mg/250ml solution for infusion Moxifloxacin is a fluoroquinolone antibiotic with a broad spectrum of activity
More informationNZQA unit standard version 4 Page 1 of 5. Demonstrate understanding of post-mortem examination of animal products used for human consumption
Page 1 of 5 Title Demonstrate understanding of post-mortem examination of animal products used for human consumption Level 4 Credits 25 Purpose This unit standard is for people who are employed in a meat
More informationCommittee for Medicinal Products for Veterinary Use
20 April 2011 EMA/CVMP/37837/2011 Veterinary Medicines and Product Data Management Monthly report of application procedures, guidelines and related documents April 2011 The CVMP monthly report includes
More informationMedicines for bees. Establishment of maximum residue limits. Principles for marketing authorisations
Medicines for bees Establishment of maximum residue limits Principles for marketing authorisations Presented by: Isaura Duarte Head of Animal and Public Health; Veterinary Medicines Sector An agency of
More informationPRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections London, 20 June 2003 PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS Meeting of 17 to 19 June
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/477/03/Final COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS POSITION PAPER REGARDING AVAILABILITY OF PRODUCTS FOR MINOR USES AND MINOR
More informationIndicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.
Zoetis UK Limited Telephone: 0845 300 8034 Website: www.zoetis.co.uk Email: customersupportuk@zoetis.com Apoquel film-coated for dogs Species: Therapeutic indication: Active ingredient: Product: Product
More informationReport from the Kennel Club/ British Small Animal Veterinary Association Scientific Committee
Report from the Kennel Club/ British Small Animal Veterinary Association Scientific Committee Summary results of the Purebred Dog Health Survey for Welsh Springer Spaniels Warning: The results of this
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationDay 90 Labelling, PL LABELLING AND PACKAGE LEAFLET
LABELLING AND PACKAGE LEAFLET A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE : Carton 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Alvegesic vet. 10 mg/ml Solution for injection for Horses, Dogs
More informationBOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin
BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: Tilmicosin 300 mg;
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT COXEVAC suspension for injection for cattle and goats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationUnits of measurement for animals for the collection of data per animal species: Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet)
for animals for the collection of data per animal species: Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet) Data collection on consumption of veterinary antimicrobials in Europe achievements,
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 20.1.2005 COM(2005) 7 final. REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT FOURTH REPORT ON THE STATISTICS ON THE NUMBER OF ANIMALS
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystimex, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients: Methyl parahydroxybenzoate 1 mg Sodium
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Xylacare 2% w/v Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Qualitative composition
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS Revised: December 2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (United Kingdom, Germany, Iceland)
More informationESSENTIAL HEARTWORM PREVENTION GUIDE PROTECT YOUR DOG FROM HEARTWORM WITHOUT HARMFUL MEDS INFORMATION PROVIDED BY PETER DOBIAS DVM
ESSENTIAL HEARTWORM PREVENTION GUIDE PROTECT YOUR DOG FROM HEARTWORM WITHOUT HARMFUL MEDS INFORMATION PROVIDED BY PETER DOBIAS DVM REASONS WHY YOU WANT TO AVOID HEARTWORM MEDS Here are the adverse events
More informationFeline blood transfusions: preliminary considerations
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Feline blood transfusions: preliminary considerations Author : Andrea Harvey Categories : RVNs Date : September 1, 2011 ABSTRACT
More informationVeterinary pharmacovigilance 2016
16 February 2017 EMA/568976/2016 Committee for Medicinal Products for Veterinary Use Public bulletin 1. Executive Summary This public bulletin is aimed at informing veterinarians and the public of the
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 21 October 2008 EMEA/CVMP/SAGAM/428938/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER ON ANTIMICROBIAL
More informationSoft-Coated Wheaten Terrier Pedigree Breed Health Survey
Soft-Coated Wheaten Terrier Pedigree Breed Health Survey Forms were received representing 147 living dogs & 12 deceased dogs. Mortality results A total of 12 deaths were reported, representing 0.21% of
More informationAntimicrobial resistance (AMR): Presentation on the joint EMA/EFSA RONAFA opinion Harmonisation of SPCs of antimicrobial veterinary medicines
Antimicrobial resistance (AMR): Presentation on the joint EMA/EFSA RONAFA opinion Harmonisation of SPCs of antimicrobial veterinary medicines EMA Veterinary Medicines Info Day 16-17 March 2017, London
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Ketamidor 100 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active substance: Ketamine (as hydrochloride) Excipient:
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
19 January 2017 EMA/CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use Guideline on the conduct of efficacy studies for intramammary products for use in cattle Draft agreed by Efficacy
More informationInformation document accompanying the EFSA Questionnaire on the main welfare problems for sheep for wool, meat and milk production
EFSA Mandate for a Scientific Opinion on the main welfare risks related to the farming of sheep for wool, meat and milk production (M-2013-0197; EFSA-Q-2013-00580) Information document accompanying the
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 February 2016 CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in Draft Draft
More informationUniversité catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France
Communicating Comprehensive Safety Data Gained from Clinical Trials to the Scientific Community: Opportunities and Difficulties from an Example with Moxifloxacin P.M. Tulkens, 1 P. Arvis, 2 F. Kruesmann,
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationMiniature Schnauzer Pedigree Breed Health Survey
Miniature Schnauzer Pedigree Breed Health Survey Forms were received representing 1019 living dogs & 78 deceased dogs. Mortality results A total of 78 deaths were reported, representing 1.39% of all deaths
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Anaestamine 100 mg/ml solution for injection Aniketam, 100 mg/ml solution for injection (EE/LT/LV) Aniketam vet., 100 mg/ml
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Dormilan solution for injection for dogs and cats [FR] Dormilan 1 mg/ml solution for injection for dogs and cats [DE, ES,
More informationCVMP Monthly report of application procedures, guidelines and related documents
8 July 2013 EMA/249895/2013 Committee for Medicinal Products for Veterinary Use (CVMP) CVMP Monthly report of application procedures, guidelines and related documents June 2013 The CVMP monthly report
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10988/066/001 Case No: 7004829 The Irish Medicines Board in exercise of the powers conferred
More informationSGV POLICY ON THE TRANSPORT OF INJURED GREYHOUNDS
SGV POLICY ON THE TRANSPORT OF INJURED GREYHOUNDS The Society of Greyhound Veterinarians has produced this document to aid decision making by track vets, and to increase awareness of the new EU Transport
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Medeson 1 mg/ml solution for injection for dogs and cats [AT, CY, CZ, DE, EL, ES, HR, IT, LT, LV, PL, PT, RO, SI, SK] Medeson,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dipen 100ml Suspension for Injection for cattle, sheep and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance
More information1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
PACKAGE LEAFLET FOR: Dormilan solution for injection for dogs and cats [FR] Dormilan 1 mg/ml solution for injection for dogs and cats [DE, PT, UK] Reanest 1 mg/ml solution for injection for dogs and cats
More informationReport from the Kennel Club/ British Small Animal Veterinary Association Scientific Committee
Report from the Kennel Club/ British Small Animal Veterinary Association Scientific Committee Summary results of the Purebred Dog Health Survey for the Saluki breed Warning: The results of this survey
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationClinical Programme. Dermatology
2018 The diagnosis and management of skin represents a major component of small animal practice. Through lectures, case discussions and practical sessions, this modular programme will enable you to learn
More informationBorzoi Pedigree Breed Health Survey
Borzoi Pedigree Breed Health Survey Forms were received representing 65 living dogs & 22 deceased dogs. Mortality results A total of 22 deaths were reported, representing 0.39% of all deaths reported in
More informationPRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 13 to 15 July 2004
European Medicines Agency Veterinary Medicines and Inspections London, 16 July 2004 EMEA/CVMP/713/04/Rev 1 PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 13 to 15 July 2004
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationVeterinary Pharmacovigilance
Veterinary Pharmacovigilance The French pharmacovigilance system and the main events of 2012 in terms of adverse reactions Annual Report October 2013 Scientific Edition Veterinary Pharmacovigilance The
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET FOR: Cadorex 300 mg/ml solution for injection for cattle, sheep and pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION
More informationESVAC meeting 3 March, 2017 EMA. Presented by Helen Jukes Co-chair RONAFA group, chair of the CVMP s Antimicrobials Working Party
Joint EMA/EFSA scientific opinion of the RONAFA advisory group on measures to reduce the need to use antimicrobial agents in animal husbandry in the EU ESVAC meeting 3 March, 2017 EMA Presented by Helen
More informationAcute Hemorrhagic Diarrhea Syndrome (AHDS) A Cause of Bloody Feces in Dogs
Acute Hemorrhagic Diarrhea Syndrome (AHDS) A Cause of Bloody Feces in Dogs No dog parent wants to clean up diarrhea. Cleaning up bloody diarrhea is even more unpleasant. Unfortunately, the development
More informationNo July 2000 REGULATION. respecting veterinarians authorisations to prescribe drugs SECTION II
REGULATION respecting veterinarians authorisations to prescribe drugs SECTION I Scope and definitions Article 1 This Regulation contains special provisions applying to veterinarians authorisations to prescribe
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationCVMP strategy on antimicrobials
1 2 3 6 November 2015 EMA/CVMP/209189/2015 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 Draft Adoption by CVMP for release for consultation 6 November 2015 Start of public consultation
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Pro Penstrep Suspension for Injection for Cattle, Sheep and Pigs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationDiclofenac in Europe an update
Diclofenac in Europe an update Diclofenac: non-steroidal anti-inflammatory substance Vet diclofenac caused 95-99% decline in Indian Gyps vultures in 20 years Vet diclofenac in Europe Safe alternative exists
More informationNovember 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas
Supply of Trimethoprim 200mg tablets by Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients from 16 and 65 years of age. November 2017 Review Nov 2019
More information